Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce

被引:46
作者
Kleinman, Nathan [6 ]
Harnett, James [1 ]
Melkonian, Arthur [2 ]
Lynch, Wendy [3 ]
Kaplan-Machlis, Barbara [4 ]
Silverman, Stuart L. [5 ]
机构
[1] Pfizer Inc, New York, NY USA
[2] HCMS Grp, Yerevan, Armenia
[3] HCMS Grp, Lakewood, CO USA
[4] Pfizer Inc, Farmington Hills, MI USA
[5] Cedars Sinai UCLA, Beverly Hills, CA USA
[6] HCMS Grp, Paso Robles, CA USA
关键词
HEALTH-CARE COSTS; RHEUMATOID-ARTHRITIS; GENERAL-POPULATION; WORK DISABILITY; ECONOMIC BURDEN; EMPLOYEES; ABSENCE; EPIDEMIOLOGY; PRODUCTIVITY; ILLNESS;
D O I
10.1097/JOM.0b013e3181bb808b
中图分类号
R1 [预防医学、卫生学];
学科分类号
100235 [预防医学];
摘要
Objectives: To calculate the fibromyalgia (FM) burden of illness (BOI) from the employer perspective and to compare annual prevalence, work output, absence, and health benefit costs of employees with FM versus osteoarthritis (OA). Methods: Retrospective regression model analysis comparing objective work output, total health benefit (health care, prescription drug, sick leave, disability, workers' compensation) costs, and absence days for FM, versus OA and NOFM cohorts, while controlling for differences in patient characteristics. Results: FM prevalence was 0.73%; OA 0. 90%. Total health benefit costs for FM were $8452 versus $11,253 (P < 0.0001) for OA and $401.3 (P < 0.0001) for NoFM, with BOI = $4439. Total absence days were 16.8 versus 19.8 (P < 0.0001) and 6.4 (P < 0.0001), respectively. FM had significantly lower annual work output than NoFM (19.5%, P = 0.003) but comparable with OA. Conclusion: FM places a significant cost, absence, and productivity burden on employers. (J Occup Environ Med. 2009;51:1384-1393)
引用
收藏
页码:1384 / 1393
页数:10
相关论文
共 44 条
[1]
ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P1494
[2]
Work disability and health system utilization in patients with fibromyalgia syndrome [J].
Al-Allaf, A. W. .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2007, 13 (04) :199-201
[3]
Health economic consequences related to the diagnosis of Fibromyalgia syndrome [J].
Annemans, L. ;
Wessely, S. ;
Spaepen, E. ;
Caekelbergh, K. ;
Caubere, J. P. ;
Le Lay, K. ;
Taieb, C. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (03) :895-902
[4]
[Anonymous], LAB FORC STAT CURR P
[5]
Patient perspectives on the impact of fibromyalgia [J].
Arnold, Lesley M. ;
Crofford, Leslie J. ;
Mease, Philip J. ;
Burgess, Somali Misra ;
Palmer, Susan C. ;
Abetz, Linda ;
Martin, Susan A. .
PATIENT EDUCATION AND COUNSELING, 2008, 73 (01) :114-120
[6]
Comorbidity of fibromyalgia and psychiatric disorders [J].
Arnold, Lesley M. ;
Hudson, James I. ;
Keck, Paul E., Jr. ;
Auchenbach, Megan B. ;
Javaras, Kristin N. ;
Hess, Evelyn V. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (08) :1219-1225
[7]
Characteristics and healthcare costs of patients with fibromyalgia syndrome [J].
Berger, A. ;
Dukes, E. ;
Martin, S. ;
Edelsberg, J. ;
Oster, G. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (09) :1498-1508
[8]
Bernard AL, 2000, ARTHRIT CARE RES, V13, P42, DOI 10.1002/1529-0131(200002)13:1<42::AID-ART7>3.3.CO
[9]
2-I
[10]
Modeling risk using generalized linear models [J].
Blough, DK ;
Madden, CW ;
Hornbrook, MC .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (02) :153-171